<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980785</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1353</org_study_id>
    <secondary_id>H-2009-0036</secondary_id>
    <secondary_id>A534255</secondary_id>
    <secondary_id>SMPH/MEDICINE/GER-AD DEV</secondary_id>
    <nct_id>NCT00980785</nct_id>
  </id_info>
  <brief_title>Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's</brief_title>
  <acronym>SEAIRA</acronym>
  <official_title>Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering&#xD;
      medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's&#xD;
      disease (AD). The purpose of the research is to see how ramipril affects a substance in the&#xD;
      body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the&#xD;
      brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of&#xD;
      getting Alzheimer's disease. This study will see if ramipril can lower the amount of&#xD;
      beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel&#xD;
      function and memory and thinking. The investigators hope that future studies will show&#xD;
      whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High blood pressure (BP) in midlife is predictive of Alzheimer's disease (AD) in later life.&#xD;
      Similarly, reductions in BP are associated with protection against AD. Treatment with&#xD;
      antihypertensive medications, specifically angiotensin converting enzyme inhibitors (ACE-I)&#xD;
      such as ramipril, is associated with up to a 55% reduction in the prevalence of AD,&#xD;
      suggesting a potentially promising role for ACE-I in the prevention of AD. It is unknown&#xD;
      however 1) whether ACE-Is will have the same effect on Cerebrospinal fluid (CSF) Aβ levels in&#xD;
      humans as in animal models 2) whether ACE-Is induce changes associated with vascular function&#xD;
      (i.e. levels of CSF angiotensin converting enzyme (ACE) and peripheral endothelial function)&#xD;
      and 3) whether there are interactions between ACE-I-induced changes in CSF Aβ, CSF ACE and&#xD;
      indices of vascular function.&#xD;
&#xD;
      One mechanism by which antihypertensives may protect against AD is via Aβ neuropathology. In&#xD;
      order to better understand the mechanisms through which ACE-I may modify CSF Aβ and possibly&#xD;
      AD risk, we propose a randomized, double-blind, placebo-controlled pilot clinical trial,&#xD;
      enrolling 20 middle-aged (age range 40 - 65 years), mildly hypertensive (between 130 - 160&#xD;
      mmHg mean systolic and between 85 - 100 mmHg mean diastolic) participants, who are adult&#xD;
      children of an individual with AD. The main objective of this trial is to examine the effects&#xD;
      of the ACE-I, ramipril, on 1) CSF Aβ levels 2) CSF ACE levels and 3) peripheral endothelial&#xD;
      function as measured by brachial artery flow-mediated vasodilation (FMD) and aortic&#xD;
      augmentation index (AAIx), in middle-aged adults with mildly elevated BP, who are at&#xD;
      increased risk of developing AD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2009</start_date>
  <completion_date type="Actual">July 26, 2011</completion_date>
  <primary_completion_date type="Actual">July 26, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>CSF Aβ42 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP® laboratories by spectrophotometric enzymatic assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril 5mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril 5 mg/day</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Altace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 40 and 65&#xD;
&#xD;
          -  Mean resting blood pressure between 130-160 systolic and 85-100 diastolic&#xD;
&#xD;
          -  Parent with Alzheimer's Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current involvement in another investigational drug trial.&#xD;
&#xD;
          -  Potassium &gt; 5.0&#xD;
&#xD;
          -  Dementia based on DSMIV criteria&#xD;
&#xD;
          -  Mini-Mental State Exam (MMSE) score &lt; 27&#xD;
&#xD;
          -  Current blood pressure medication (&lt; 4 months from screening)&#xD;
&#xD;
          -  Weight loss medication&#xD;
&#xD;
          -  Contraindications for LP&#xD;
&#xD;
          -  Know diagnosis or history of hospitalization due to congestive heart failure&#xD;
&#xD;
          -  Elevated creatinine (females &gt; 1.3 mg/dL or males &gt; 1.4 mg/dL at baseline)&#xD;
&#xD;
          -  Diabetes Type I and II&#xD;
&#xD;
          -  Know adverse reaction to an ACE-I or an angiotensin receptor blocker&#xD;
&#xD;
          -  Pregnant of nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M Carlsson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wisconisn Alzheimer's Disease Research Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wisconsinadrc.wisc.edu/prevention_research.shtml</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593582/</url>
    <description>The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial</description>
  </link>
  <reference>
    <citation>Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147-56.</citation>
    <PMID>22776970</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>February 14, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT00980785/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Wisconsin Alzheimer's Disease Research Center (ADRC) registry and from the community for the clinical trial, Studying the Effects of Antihypertensives in Individuals at Risk for Alzheimer's (SEAIRA).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
        </group>
        <group group_id="P2">
          <title>Active</title>
          <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
        </group>
        <group group_id="B2">
          <title>Active</title>
          <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="6.7"/>
                    <measurement group_id="B2" value="56.3" spread="6.1"/>
                    <measurement group_id="B3" value="54.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
        <description>CSF Aβ42 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.</description>
        <time_frame>Baseline to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
          <description>CSF Aβ42 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="78.7"/>
                    <measurement group_id="O2" value="-31.71" spread="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney test</non_inferiority_desc>
            <p_value>0.836</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>78.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney Test</non_inferiority_desc>
            <p_value>0.836</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-31.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>90.6</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
        <description>CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP® laboratories by spectrophotometric enzymatic assay.</description>
        <time_frame>Baseline to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
          <description>CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP® laboratories by spectrophotometric enzymatic assay.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.21"/>
                    <measurement group_id="O2" value="-0.63" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney Test</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney Test</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
        <description>FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.</description>
        <time_frame>Baseline to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
          <description>FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.</description>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="1.56"/>
                    <measurement group_id="O2" value="-0.29" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney Test</non_inferiority_desc>
            <p_value>0.755</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.56</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney test</non_inferiority_desc>
            <p_value>0.755</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.23</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
        <description>Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.</description>
        <time_frame>Baseline to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo</title>
          <description>Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.</description>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="8.9"/>
                    <measurement group_id="O2" value="-1.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney test</non_inferiority_desc>
            <p_value>0.491</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.9</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney test</non_inferiority_desc>
            <p_value>0.491</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.2</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo&#xD;
Placebo: Matching Placebo</description>
        </group>
        <group group_id="E2">
          <title>Active</title>
          <description>Ramipril 5mg/day&#xD;
Ramipril: Ramipril 5 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations included small sample size, short duration of trial, and lack of A-beta neuropathology.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cynthia M. Carlsson, MD, MS</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health</organization>
      <phone>608-256-1901 ext 11691</phone>
      <email>cmc@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

